Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Erlotinib Intercalation in EGFR-Mutated NSCLC
NCT02795884Phase 3Withdrawn
- Sponsor
- Yonsei University
- Start
- Jun 2016
- Primary completion
- Nov 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of erlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Yonsei University. Primary endpoint: Disease-free survival at 3 years. Planned start Jun 2016; status: withdrawn.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02795884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02795884.